Recent Quotes (30 days)

You have no recent quotes
chg | %

Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for MYGN
-0.14 (-0.42%)
After Hours: 32.91 0.00 (0.00%)
Sep 19, 4:45PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.72 - 33.22
52 week 15.15 - 33.42
Open 32.92
Vol / Avg. 618,890.00/1.14M
Mkt cap 2.25B
P/E 104.79
Div/yield     -
EPS 0.31
Shares 68.44M
Beta 0.26
Inst. own 120%
Dec 1, 2017
Myriad Genetics Inc Annual Shareholders Meeting (Estimated) - 11:00AM EST - Add to calendar
Oct 30, 2017
Q1 2018 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2017
Myriad Genetics Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
Myriad Genetics Inc at Wells Fargo Healthcare Conference
Sep 5, 2017
Myriad Genetics Inc Corporate Call to Discuss the Launch of riskScore - Webcast
Aug 8, 2017
Q4 2017 Myriad Genetics Inc Earnings Call - Webcast
Aug 8, 2017
Q4 2017 Myriad Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin 6.33% 2.80%
Operating margin 8.48% 6.40%
EBITD margin - 12.67%
Return on average assets 4.09% 2.05%
Return on average equity 6.73% 2.86%
Employees 2,400 -
CDP Score - -


320 S Wakara Way
SALT LAKE CITY, UT 84108-1214
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
R. Bryan Riggsbee CPA Chief Financial Officer, Treasurer
Age: 45
Bio & Compensation  - Reuters
Virginia C. Drosos President of Assurex Health, Inc.
Age: 54
Bio & Compensation  - Reuters
Alexander Ford President of Myriad Genetic Laboratories, Inc.
Age: 49
Bio & Compensation  - Reuters
Ralph L. McDade Ph.D. President of Myriad RBM, Inc
Age: 61
Bio & Compensation  - Reuters
Bernard F. Tobin President of Crescendo Bioscience, Inc
Age: 59
Bio & Compensation  - Reuters
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 60
Bio & Compensation  - Reuters